



**What's New**

**14.03.2019**

**Trade Margin Rationalisation of selected non-scheduled anti-cancer drugs - NPPA requires details of Imported formulations.**

Invoking paragraph 19 of DPCO, 2013, the Government has put a cap on trade margin of 30% on selling price for the select Non-Scheduled Anti-Cancer Drugs containing any of the 42 drugs listed in Order i.e. SO.No. 1042 (E) dated 27.02.2019.

Accordingly, NPPA issued Office Memorandum dated 08.03.2019 and 11.03.2019 containing a list of brands with revised MRP's on the basis of data submitted by manufacturers.

Now, NPPA has directed manufacturers to provide the details of Landed cost for Imported Formulations as per attached format in Annexure III by 15<sup>th</sup> March,2019.

The information sought in Annexure III may be emailed to [amarpal.sawhney@nic.in](mailto:amarpal.sawhney@nic.in) and [prakash.hemani@gov.in](mailto:prakash.hemani@gov.in) .

Further, the manufacturers, who have not furnished the data in Annexure I of Order dated 27.02.2019 and Annexure II of Office Memorandum dated 06.03.2019 are again directed to furnish the requisite data immediately along with Annexure III

**Click here**

**[Office Memorandum and Annexure III](#)**